Biofil Chemicals & Pharmaceuticals Ltd
NSE: BIOFILCHEM BSE: 524396
₹34.30
(-0.38%)
Thu, 30 Apr 2026, 03:25 pm
Market Cap559.82M
PE Ratio20.13
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KBiofil Chemicals & Pharmaceuticals Analysis
dividend
- Unable to evaluate Biofil Chemicals and Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Biofil Chemicals and Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Biofil Chemicals and Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Biofil Chemicals and Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Biofil Chemicals and Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (105.8%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 24.4x debt.
- Biofil Chemicals and Pharmaceuticals has no long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (33.6% vs 9.9% today).
- Interest payments on debt are well covered by earnings (EBIT is 10.9x coverage).
- Biofil Chemicals and Pharmaceuticals's level of debt (9.9%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The average tenure for the Biofil Chemicals and Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
misc
- Biofil Chemicals and Pharmaceuticals is not covered by any analysts.
- Biofil Chemicals and Pharmaceuticals has significant price volatility in the past 3 months.
past
- Biofil Chemicals and Pharmaceuticals's 1-year earnings growth exceeds its 5-year average (100.2% vs 2.6%)
- Biofil Chemicals and Pharmaceuticals's year on year earnings growth rate has been positive over the past 5 years.
- Biofil Chemicals and Pharmaceuticals's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (100.2% vs 22.7%).
- Biofil Chemicals and Pharmaceuticals used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Biofil Chemicals and Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Biofil Chemicals and Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- Biofil Chemicals and Pharmaceuticals is good value based on assets compared to the IN Pharmaceuticals industry average.
- Biofil Chemicals and Pharmaceuticals's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Biofil Chemicals and Pharmaceuticals's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Biofil Chemicals and Pharmaceuticals is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Biofil Chemicals and Pharmaceuticals is overvalued based on earnings compared to the India market.
- BSE:524396 is up 2% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524396 is up 2% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800